Evaluation of a single daily dose of naproxen in osteoarthritis.

P M Brooks, L G Cleland, A L Haski, D B Hempton, J N Muller, L J Hills
{"title":"Evaluation of a single daily dose of naproxen in osteoarthritis.","authors":"P M Brooks,&nbsp;L G Cleland,&nbsp;A L Haski,&nbsp;D B Hempton,&nbsp;J N Muller,&nbsp;L J Hills","doi":"10.1093/rheumatology/21.4.242","DOIUrl":null,"url":null,"abstract":"<p><p>A six-week double-blind randomized cross-over trial comparing the safety and efficacy of 250 mg naproxen administered twice daily and 500 mg naproxen administered as a single dose at night in osteoarthritic patients stabilized on naproxen 250 mg twice daily is reported. There was no significant difference between the two regimens. This study provides evidence that naproxen can be given to patients with osteoarthritis on a single-daily-dose regimen without any loss of anti-inflammatory/analgesic activity.</p>","PeriodicalId":76486,"journal":{"name":"Rheumatology and rehabilitation","volume":"21 4","pages":"242-6"},"PeriodicalIF":0.0000,"publicationDate":"1982-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/21.4.242","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rheumatology/21.4.242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

A six-week double-blind randomized cross-over trial comparing the safety and efficacy of 250 mg naproxen administered twice daily and 500 mg naproxen administered as a single dose at night in osteoarthritic patients stabilized on naproxen 250 mg twice daily is reported. There was no significant difference between the two regimens. This study provides evidence that naproxen can be given to patients with osteoarthritis on a single-daily-dose regimen without any loss of anti-inflammatory/analgesic activity.

评价单次每日剂量的萘普生治疗骨关节炎。
据报道,一项为期六周的双盲随机交叉试验比较了250 mg萘普生每日两次给药和500 mg萘普生夜间单剂量给药对稳定在250 mg萘普生每日两次的骨关节炎患者的安全性和有效性。两种治疗方案之间没有显著差异。这项研究提供了证据,证明骨关节炎患者可以每天给药一次,而不会失去抗炎/镇痛活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信